HBRM Stock Plummets 99% on PNK: Herborium Group Faces Severe Decline

HBRM stock has collapsed dramatically, trading at just $0.000001 USD on the PNK exchange as of April 22, 2026. The botanical therapeutics company has lost 99% of its value, marking one of the most severe declines in the healthcare sector. Herborium Group, Inc., which develops herbal medicinal products like AcnEase and sexual health supplements, now carries a market cap of just $545,971. The company’s financial metrics reveal deep structural problems, with negative equity and minimal cash reserves. Investors tracking HBRM stock should understand the severity of this situation before making any decisions.

HBRM Stock Price Collapse: What Happened

HBRM stock has experienced a catastrophic decline, trading at $0.000001 with a -99% change from its previous close of $0.0001. The stock’s day range shows it hit a low of $0.000001 and a high of $0.0001, reflecting extreme volatility. Over the past year, HBRM stock has fallen 50%, while the five-year decline stands at -96.15%. Volume surged to 25.14 million shares, far exceeding the average of 647,435 shares, indicating panic selling and liquidation activity.

The company’s year-high of $0.0001 and year-low of $0.00001 show the stock has been under pressure throughout 2026. With only 2 full-time employees and headquarters in Fort Lee, New Jersey, Herborium Group operates as a micro-cap entity with minimal operational capacity. The botanical therapeutics sector has faced headwinds, but HBRM’s collapse appears company-specific rather than industry-wide.

Financial Metrics Show Severe Distress

HBRM stock’s fundamentals reveal alarming red flags across every metric. The company reports negative shareholders’ equity of -$0.000394 per share, indicating liabilities exceed assets. Book value per share stands at -$0.000364, while tangible book value is -$0.000375, both deeply negative. Revenue per share is minimal at $0.0000722, yet the company still posts a net loss per share of -$0.0000142.

The current ratio of 0.0042 signals the company cannot cover short-term obligations, while the debt-to-assets ratio of 7.49 shows extreme leverage. Operating margins are -30.19%, and return on assets is -108.37%, demonstrating the company burns cash on every operation. Working capital is negative $3.43 million, and the company holds virtually no cash per share at $0.00000047. These metrics confirm HBRM stock faces existential financial challenges.

Meyka AI Rating: Strong Sell with D+ Grade

Meyka AI rates HBRM with a grade of D+, reflecting severe fundamental weakness. The rating carries a Strong Sell recommendation based on comprehensive analysis. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company scores critically low across all valuation metrics: DCF score of 1, ROE score of 2, ROA score of 1, debt-to-equity score of 1, and PE score of 1.

Every component receives a Strong Sell recommendation except ROE, which earns a Sell rating. The overall score of 59.85 places HBRM in the lowest tier. These grades are not guaranteed and we are not financial advisors. The rating reflects the company’s inability to generate profits, manage debt, or create shareholder value in any meaningful way.

Market Sentiment: Trading Activity and Liquidation

Trading activity in HBRM stock shows signs of forced liquidation and panic selling. Volume of 25.14 million shares represents 38x the average daily volume, indicating massive position unwinding. The Money Flow Index (MFI) reads 82.12, signaling overbought conditions typical of capitulation selling. The Stochastic indicator shows %K at 83.16 and %D at 83.28, both in overbought territory, suggesting sellers have exhausted demand.

The Rate of Change (ROC) is -50%, confirming downward momentum. The Average True Range (ATR) shows minimal price movement, reflecting the stock’s penny-stock status. On-Balance Volume (OBV) of 9.26 million indicates volume has been predominantly on the sell side. The ADX reading of 58.57 confirms a strong downtrend is in place. These technical signals suggest HBRM stock may continue lower as remaining holders exit positions.

Herborium Group’s Business Model Under Pressure

Herborium Group develops botanical therapeutics including AcnEase for acne and rosacea, sexual health products, energy supplements like Lasting Energy, and specialized formulations like ProstAid and CardioVitae. The company operates with just 2 employees and distributes through specialty retailers and e-commerce in the US, UK, and continental Europe. Revenue per share of $0.0000722 suggests annual revenues are minimal, likely under $1 million.

The company’s gross profit margin of 62.99% shows products carry decent margins, but operating expenses consume all revenue and more. Sales, general, and administrative costs represent 74.15% of revenue, while R&D takes another 19.03%. With negative operating margins and no path to profitability, the business model has failed to gain traction. Track HBRM on Meyka for real-time updates on this distressed situation.

Forecast and Future Outlook

Meyka AI’s forecast model projects HBRM stock price at $0.0000240 over one year, implying 2,300% upside from current levels. However, this forecast assumes operational improvements that show no signs of materializing. The three-year forecast of $0.0000204 and five-year forecast of $0.0000159 suggest continued pressure. The seven-year forecast of $0.0000498 reflects model assumptions about potential recovery, but these remain speculative.

Forecasts are model-based projections and not guarantees. Given the company’s negative equity, minimal cash, and inability to generate profits, the path to recovery appears blocked. The company would need dramatic operational changes, new capital infusion, or strategic acquisition to reverse course. Without such intervention, HBRM stock faces further deterioration as the company burns through remaining resources.

Final Thoughts

HBRM stock represents an extreme case of financial distress in the healthcare sector. Trading at $0.000001 USD on the PNK exchange, the stock has lost 99% and faces a D+ rating with a Strong Sell recommendation from Meyka AI. The company’s negative equity, minimal revenue, and inability to cover operating expenses create an unsustainable situation. With only 2 employees and a market cap of $545,971, Herborium Group lacks the resources to execute a turnaround. Volume surges and technical indicators suggest forced liquidation continues. Investors holding HBRM stock should carefully evaluate their positions, as further deterioration appears likely without major operational or financial restructuring. The company’s botanical therapeutics products show market potential, but execution has failed completely.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.